Sodium-Glucose Transporter 2
"Sodium-Glucose Transporter 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sodium-glucose transporter that is expressed in the luminal membrane of the PROXIMAL KIDNEY TUBULES.
| Descriptor ID |
D051297
|
| MeSH Number(s) |
D12.776.157.530.450.625.437.750 D12.776.157.530.500.750.750 D12.776.157.530.937.700 D12.776.543.585.450.625.562.750 D12.776.543.585.500.750.750 D12.776.543.585.937.825
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sodium-Glucose Transporter 2".
Below are MeSH descriptors whose meaning is more specific than "Sodium-Glucose Transporter 2".
This graph shows the total number of publications written about "Sodium-Glucose Transporter 2" by people in this website by year, and whether "Sodium-Glucose Transporter 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sodium-Glucose Transporter 2" by people in Profiles.
-
Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes Obes Metab. 2022 11; 24(11):2071-2080.
-
Col4a3-/- Mice on Balb/C Background Have Less Severe Cardiorespiratory Phenotype and SGLT2 Over-Expression Compared to 129x1/SvJ and C57Bl/6 Backgrounds. Int J Mol Sci. 2022 Jun 15; 23(12).
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
-
Off-label use of sodium glucose co-transporter inhibitors among adults in type 1 diabetes exchange registry. Diabetes Obes Metab. 2022 01; 24(1):171-173.
-
Are All SGLT2 Inhibitors Created Equal? Clin J Am Soc Nephrol. 2021 09; 16(9):1309-1311.
-
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. Cardiovasc Drugs Ther. 2022 12; 36(6):1091-1108.
-
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition. Diabetes. 2020 05; 69(5):882-892.
-
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
-
Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. Curr Heart Fail Rep. 2017 12; 14(6):445-453.
-
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.